Chromatin/Epigenetics
Epigenetics is the heritable modifications in gene expression that is not associated with changes in DNA sequence. Epigenetic modifications occur mostly on DNA or on the histone octamer. There are several types of epigenetics modifications, DNA methylation by DNA-methyl transferase (DNMT) and covalent modification of histones (e.g. acetylation, methylation, phosphorylation and ubiquitination). Histone acetylation by histone acetyltransferases (HATs) is involved in transcriptional activation, whereas histone deacetylation by histone deacetylases (HDACs) is connected with transcriptional repression. Histone demethylation is associated with lysine-specific demethylase (LSD) and JmjC domain containing histone demethylase (JHDM).
The nucleosome is consisted of four histone proteins (H2A, H2B, H3, and H4), they are primary building block of chromatin. The addition and removal of specific chemical groups refers to as epigenetic marks, it regulates chromatin structure and affects gene expression. Moreover, RNA is intimately involved in the formation of a repressive chromatin state.
Epigenetic mechanism responds to environmental changes at the cellular level and thus influences cellular plasticity. Chromatin and epigenetic regulation play a significant role in the programming of the genome during development and stress response, defects in epigenetics can lead to cancer, inflammation and metabolic disorders etc.
- A4511 CercosporamideTarget: JAK|MNKSummary: Mnk2 and JAK3 inhibitor
- A4512 Cucurbitacin ITarget: STAT|JAKSummary: STAT3/JAK2 signaling inhibitor
- A4513 Lestaurtinib1 CitationSummary: JAK2/FLT3/TrkA inhibitor
- A4515 SD 1008Summary: Inhibitor of JAK2/STAT3 signaling pathway,apoptosis inducer
- A4516 TCS 21311Summary: JAK3 inhibitor
- A4517 ZM 449829Summary: JAK3 inhibitor
- A4518 UNC 926 hydrochlorideSummary: Inhibitor of methyl lysine reader domain
- A4519 PIM-1 Inhibitor 2Summary: Potent Pim-1 kinase inhibitor
- A4520 R8-T198wtSummary: Pim-1 kinase inhibitor
- A4521 TCS PIM-1 1Summary: Pim-1 kinase inhibitor,ATP-competitve